Bradley Hunt
About Bradley Hunt
Bradley W. Hunt, age 56, is an independent Class II director of MediaAlpha (MAX) appointed in March 2025. He spent 18 years with UnitedHealth Group (UHG), including serving as CEO of Optum Rx Home Delivery Pharmacy (Jan 2024–Mar 2025), SVP Strategic Initiatives (Aug 2022–Jan 2024), and Chief Marketing Officer for Government Programs and Insurance Solutions (2008–2022). He holds an MBA from Duke University’s Fuqua School of Business and a BS in Business Administration from Miami University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| UnitedHealth Group (UHG) | CEO, Optum Rx Home Delivery Pharmacy | Jan 2024–Mar 2025 | Led operations of home delivery pharmacy unit |
| UnitedHealth Group (UHG) | SVP, Strategic Initiatives | Aug 2022–Jan 2024 | Led enterprise programs incl. marketing technology and a key JV |
| UnitedHealth Group (UHG) | CMO, Government Programs | Jan 2015–Aug 2022 | Led omnichannel marketing for Medicare, DSNP, ACA units |
| UnitedHealth Group (UHG) | CMO, Insurance Solutions | Jul 2008–Jan 2015 | Marketing leadership across insurance solutions |
| IAC’s Entertainment Publications, Inc. | General Manager – Consumer Division | Pre-2008 | Consumer division leadership |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Public company boards | None disclosed | — | Proxy states no other director (including Hunt) currently serves, or in past five years has served, on boards of other public reporting companies/investment companies |
Board Governance
- Committee assignments: Member, Nominating & Corporate Governance Committee; post-Annual Meeting composition: Kathy Vrabeck (Chair), Bradley Hunt, and Lara Sweet (all independent) .
- Independence: Board affirmed Hunt’s independence under NYSE standards .
- Attendance: Board met 6 times in 2024; each incumbent director attended ≥75% of Board and committee meetings (Hunt joined in 2025; attendance expectation communicated) .
- Election signal: At the May 14, 2025 Annual Meeting, Hunt was elected with 57,002,361 votes for, 79,090 against, 66,756 abstain; broker non-votes 3,985,987 .
- Indemnification: Company entered standard indemnification agreement upon his appointment .
- No related-party exposure: Company disclosed no arrangements or transactions under Item 404(a) involving Hunt and no appointment arrangements; no family relationships .
Fixed Compensation
| Component | Amount/Terms | Notes |
|---|---|---|
| Annual Board retainer (cash) | $40,000 | Payable quarterly in arrears |
| Annual equity retainer (RSUs) | $175,000 grant value | RSUs granted at each Annual Meeting; shares determined by 20-day avg. closing price, rounded up to next 50 shares |
| Chairperson of the Board fee | $25,000 | If serving as Chair (not applicable to Hunt) |
| Lead Independent Director fee | $20,000 | If serving as Lead Independent (not applicable) |
| Committee chair fees | Audit $20,000; Compensation $15,000; Nominating & Gov $10,000 | Hunt is a committee member, not chair |
| Committee membership fees | Audit $10,000; Compensation $7,500; Nominating & Gov $5,000 | Hunt eligible for $5,000 as Nominating & Gov member |
| Meeting fees | None disclosed | No per-meeting fees disclosed |
| Proration for mid-year joins | Prorated cash and RSUs | Directors joining mid-year receive prorated retainers and RSUs |
Performance Compensation
| Equity Award | Grant Date | Shares/Value | Vesting | Notes |
|---|---|---|---|---|
| Director RSU (Annual) | May 14, 2025 | 23,100 shares (Form 4 “A”) | Vests in full on earlier of one-year from grant or next Annual Meeting, subject to service | |
| Director RSU (Prorated upon appointment) | Mar 31, 2025 | 2,350 shares (Form 4 “A”) | Same vesting convention per policy |
- Director compensation at MAX does not use performance metrics (e.g., revenue/EBITDA/TSR) for non-employee directors; equity awards are time-based RSUs per policy .
Other Directorships & Interlocks
| Person | External Public Boards | Committees/Roles | Potential Interlocks |
|---|---|---|---|
| Bradley Hunt | None disclosed | — | None disclosed; Hunt was not nominated pursuant to the Stockholders’ Agreement (no voting agreement in place for him) |
Expertise & Qualifications
- Healthcare and insurance domain expertise, strategic marketing leadership, digital transformation and consumer engagement; large-organization management experience .
- Education: MBA (Duke Fuqua); BS Business Administration (Miami University) .
Equity Ownership
| Date | Transaction Type | Shares Transacted | Post-Transaction Beneficial Holdings | Security | Filing URL |
|---|---|---|---|---|---|
| 2025-05-14 | Award (Form 4 “A”) | 23,100 | 25,450 | Class A Common Stock | |
| 2025-03-31 | Award (Form 4 “A”) | 2,350 | 2,350 | Class A Common Stock | |
| 2025-03-31 | Initial filing (Form 3) | — | — | — |
- Outstanding shares at record date (Mar 20, 2025): 55,895,646 Class A and 11,574,029 Class B . Based on 25,450 Class A shares held after 2025-05-14, Hunt’s Class A ownership is approximately 0.046% of Class A outstanding (25,450 ÷ 55,895,646; calculated from Form 4 holdings and proxy outstanding counts) .
- Stock ownership guidelines: Directors must own at least 5× annual cash retainer ($200,000 equivalent) and must retain 75% of net shares acquired until compliant . Compliance status for Hunt is not disclosed .
Governance Assessment
- Board effectiveness: Hunt strengthens the Nominating & Corporate Governance Committee’s oversight of director nominations, board evaluation, CEO succession, and ESG matters; committee met 4 times in 2024 and is fully independent .
- Independence and shareholder mandate: Board affirmed Hunt’s independence; strong shareholder support for his election (57.0M for vs. 79k against) indicates investor confidence .
- Compensation alignment: Director pay uses a cash retainer plus time-based RSUs, with clear vesting and prorated treatment on mid-year appointment; ownership guidelines require meaningful skin-in-the-game .
- Conflicts/related-party exposure: No Item 404(a) related-party transactions or appointment arrangements; no family relationships; Hunt was not a Stockholders’ Agreement nominee, reducing sponsor interlocks risk .
- Shareholder feedback context: 2025 say-on-pay passed by a wide margin (51,553,713 for; 5,560,610 against), suggesting overall compensation governance support; while focused on NEOs, it is a positive signal for the board’s oversight .
RED FLAGS: None identified for Hunt. No pledging or hedging disclosures were noted for him; no fee waivers or sponsor affiliations; attendance expectations met broadly at board level in 2024 (Hunt joined in 2025) .